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Abstract 
 
Background: Intracranial solitary fibrous tumors (SFT) are rare neoplasms of the brain with 
a typical benign and slow-growing behavior. The gold-standard of treatment is gross total 
resection (GTR). However, sometimes this approach is dangerous or not feasible because of 
anatomical considerations. Therefore, approaches like stereotactic radiosurgery (SRS) are 
currently being evaluated. 
Clinical Presentation: The authors present a 59-year-old male patient with a month history 
of language and humor disorders with headaches and right central facial paresis. Imaging 
studies revealed an anterior left temporal mass with edema and mass effect. GTR was 
performed, with histology revealing a SFT. During follow-up, regrowth with invasion of the 
left cavernous sinus and optical nerve compression was reported. Subtotal resection (STR) 
was performed leaving only an intracavernous sinus residue. Pathology once again was 
consistent with SFT. The tumor residue was treated with linear accelerator-based SRS. 
During follow-up a slow tumor regrowth was observed in the first 12 months after SRS, with 
posterior stabilization and shrinkage. The shrinkage was only observed 24 months post-SRS. 
Conclusion: our case represents the successful treatment of an SFT using SRS. It strengthens 
the role of SRS in managing these tumors when surgery is not an option. 
 
Introdução: os tumores fibrosos solitários intracranianos (TFS) são neoplasias raras do 
encéfalo com características benignas e crescimento lento. O tratamento principal passa pela 
ressecção total do tumor (RTT). No entanto, esta abordagem nem sempre é possível por 
condicionantes anatómicas. Assim, a radiocirurgia estereotácica (RCE) tem sido estudada 
como terapêutica adjuvante. 
Caso clínico: Os autores apresentam um doente de 59 anos, do sexo masculino, com história 
de alterações da linguagem e do humor, associadas a cefaleias e parésia facial central direita 
com a duração de um mês. Os estudos imagiológicos revelaram presença de um tumor na 
região temporal esquerda, com edema e efeito de massa. Foi efetuada RTT, com histologia 
compatível com TFS. Durante o período de seguimento, foi detetada nova lesão, com invasão 
do seio cavernoso esquerdo e compressão do nervo óptico. Foi realizada ressecção subtotal, 
deixando apenas um resíduo intracavernoso. O exame histológico foi novamente compatível 
com TFS. O resíduo tumoral foi tratado com RCE (acelerador linear de partículas). No 
seguimento, observou-se crescimento lento da lesão durante os primeiros 12 meses, com 
estabilização e posterior involução da lesão, apenas 24 meses pós-RCE. 
Conclusão: o caso apresentado representa o tratamento bem-sucedido de um TFS 
recorrendo a RCE, reforçando a sua potencial utilidade na terapêutica adjuvante de tumores 
deste tipo. 
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olitary fibrous tumor (SFT) is a 
rare neoplasm that was initially 
described in the pleura. It was first 
reported in the central nervous system 
(CNS) in 1996 by Carneiro et al1. Since 
then, there have been several case reports 
and series that have expanded our 
clinicopathological knowledge about this 
entity. 
SFTs of the CNS are classified by World 
Health Organization (WHO) as tumors of 
the meninges of mesenchymal origin2. 
Their behavior is mostly benign and slow-
growing. However, there have been 
literature reports of cases in which 
malignant transformation occurred, 
sometimes with distant metastatic 
dissemination3,4. 
Their precise incidence is unknown, but 
it is thought that they may represent about 
0,09% of all tumors that affect the 
meninges3. Most reported cases involve 
middle-aged patients (around the 5th 
decade), and there seems to be an equal 
distribution between genders. There seems 
to be a higher percentage of intracranial 
tumors in relation to intraspinal ones (76% 
versus 24%, respectively)5. 
There is no typical clinical presentation, 
since it always varies according to the 
specific location and size of the tumor. The 
overall existing literature agrees on the fact 
that SFTs may arise in any part of the CNS, 
having been described a wide array of 
different locations, such as: tentorium 
cerebelli, frontal convexity, cerebropontine 
angle, cerebral ventricles, falx cerebri or 
posterior fossa, as well as various locations 
in the spine5. 
In terms of image features, SFTs of the 
CNS usually present themselves as iso-
dense on computed tomography (CT) 
comparing with brain parenchyma (with 
homogeneous contrast enhancement), as 
iso-intense on T1-weighted magnetic 
resonance imaging (MRI) (with strong 
enhancement with gadolinium) and may 
show up as either hyper or hypo-intense on 
T2-weighted MRI5. A published case states 
that PET imaging shows a restricted 
diffusion with an elevated peak of myo-
inositol6. 
Histopathological analysis throughout 
the various case reports and series reveals 
that SFTs are composed of a mixed pattern 
of bundles of spindle cells that alternate 
with thick strands of collagen in the 
intercellular matrix7. These cells are 
fusiform, with an oval nucleus and 
eosinophil cytoplasm8. They present 
branching, thin-walled, non-hyaline 
vascular channels5. Mitotic indexes are 
low, with Ki-67 usually presenting lower 
than 5%9. 
Immunohistochemical data shows that 
SFTs are strongly and diffusely stained by 
CD34, vimentin, bcl-25. CD99 and CD117 
staining is also positive6,8. Staining is 
S 
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negative with epithelial membrane antigen 
(EMA), S-100 protein, glial fibrillary acidic 
protein (GFAP), desmin or vascular 
antigens. Cytogenetic studies are very 
limited, and no single pathognomonic 
feature has been found so far6. 
As mentioned before, SFTs of the CNS, 
in a vast majority, present themselves 
attached to the meninges and well 
circumscribed. Because of this, differential 
diagnosis between SFTs and other more 
common meningeal tumors, namely 
meningiomas and hemangiopericytomas 
(HPC), must be made. The distinction 
between SFTs and meningiomas can be 
based on the fact that the former lack vessel 
hyalinization that is seen in the histological 
analysis of the latter5. The differential 
diagnosis between SFTs and HPCs, 
however, is a quite more controversial and 
complex matter. In fact, up until very 
recently, these were seen as two distinct 
entities by the WHO classification of CNS 
tumorsThe distinction between SFTs and 
had been a growing tendency for 
pathologists to consider both as part of the 
same spectrum of neoplasiathere is a 
Bookmark not defined.. This happened because of 
increasingly more reports of overlapping of 
both pathological and prognostic featuresIt 
The term hemangiopericytoma had become 
so underused in recent times, that its 
importance was related solely to its 
historical distinct clinicopathological 
correlations, namely high recurrence rates 
and long-term risk of systemic metastasis. 
It has also been observed that both SFTs 
and HPCs shared inversions at 12q13, 
fusing the NAB2 and STAT6 genes13,14, 
which leads to a STAT6 nuclear expression 
that can be detected by 
immunohistochemistry15. Facing these 
numerous changes, the newly-released 
2016 WHO classification of tumors of the 
CNS has revised its classification system 
and created the combined term solitary 
fibrous tumor / hemangiopericytoma, 
recognizing that it has both entities are 
overlapping, if not identical16. 
Grading of this new combined entity has 
also been revised in the new classification, 
having been assigned three grades: a grade 
I corresponding to a high collagenous, low 
cellularity, spindle-cell lesion (the 
“traditional” SFT); a grade II, more 
cellular, less collagenous tumor with plump 
cells and “staghorn” vasculature 
(previously diagnosed as HPC); a grade III, 
a tumor with 5 or more mitoses per 10 high-
power fields (the old anaplastic HPC)12. 
Surgical treatment is the gold standard, 
being regarded as the main prognostic 
factor5,17, as there seems to be a much lower 
chance of recurrence in patients after gross 
total resection (GTR), than in those after 
subtotal resection (STR)5. Other factors, 
like malignancy-suggestive histology, or 
high MIB-1 index, while useful, are not 
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enough to predict the rate of recurrence18. 
In cases submitted to GTR, disease-free 
survival of up to 20 years has been reported. 
Nevertheless, the unpredictable behavior of 
these tumors in terms of recurrence 
demands that patients must be followed in 
the long-term, regardless of the extent of 
surgical removal9. 
In patients with atypical SFTs or where 
only incomplete resection is possible, the 
role of adjuvant therapy is still unknown. In 
the existing literature, no conclusions could 
be drawn regarding the need or usefulness 
of pre-operative embolization and adjuvant 
radiotherapy or chemotherapy. However, a 
few cases of successful use of Stereotactic 
Radiosurgery (SRS) in intracranial SFTs 
after STR have been reported19,20,21.  
SRS describes a treatment modality that 
uses stereotactic localization to administer 
large radiation doses with an accentuated 
gradient to a precise intracranial locus, 
exposing at the same time the surrounding 
tissues to tolerable amounts of radiation. 
The dose is usually administered in a single 
treatment session. It is useful for well 
circumscribed lesions, preferably with less 
than 2.5-3 cm diameter. There are several 
published uses of this treatment modality, 
however the “classic” lesion for which it is 
used is the arterial-venous malformation 
(AVM)22,23,24. Its usage for tumors is 
controversial, because it can cause delayed 
side-effects in young patients and it is 
generally not indicated for infiltrating 
tumors25. Still, SRS has been used for the 
treatment of lesions such as acoustic 
neuromas26, pituitary adenomas, 
craniopharyngiomas, pineal tumors, brain 
metastases, high grade gliomas and 
meningiomas of the cavernous sinus27. It 
has also been used for the management of 
chronic pain28 (including trigeminal 
neuralgia29,30) and pallidotomies for 
Parkinson’s disease. It is also considered an 
option when patients refuse open brain 
surgery for any reason. SRS is 
contraindicated in cases of compressive 
tumors of the spinal cord or medulla 
because of its significant risk of neurologic 
injury. 
Currently, SRS may utilize different 
types of penetrating energy, such as protons 
and heavy-charged particles, which are 
cyclotron or synchrotron-generated, or 
photon devices, such as modified linear-
accelerators (LINACs) or the Gamma-
Knife (GKRS). While high-energy protons 
offer the advantage to improve tumor 
control in small deep-sited localizations, 
relatively sparing the normal surrounding 
tissue, they come at great expense of 
building and maintenance. Therefore, 
photon devices are currently the most used. 
Among these, LINACs use x-ray beams 
that are produced by the collision of 
accelerated electrons with a metal target; 
multiple noncomplanar arcs converge at a 
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single isocenter, creating a nearly sphere-
shaped dose distribution. Adjustment of 
several parameters (such as arc number, 
length, angles and weight) and the use of 
tertiary circular collimators that are present 
in most radiosurgery units decrease the 
irradiation of adjacent crucial structures. 
LINACs have proved to be an excellent 
radiosurgical option, particularly in cases of 
larger tumor volumes or when fractionated 
radiosurgery is needed31,32,33. On the other 
hand, the gamma knife contains an array of 
multiple 60Co sources aligned with a 
collimation system that directs each of the 
radiation beams to a very precise focal 
point, thus dealing high radiation doses to 
the desired location, while peripheral dose 
levels remain low. 
In terms of imaging modalities, CT is the 
preferred one, providing the best accuracy 
in comparison with the rest of available 
options. When MRI is required, image-
fusion techniques are used with a 
stereotactic-CT and a non-stereotactic-
MRI. Stereotactic angiography and digital 
subtraction angiography are rarely required 
and may even introduce errors in treatment 
planning34,35,36,37. 
Morbidity and mortality associated with 
this treatment method are extremely low. 
Immediate mortality from the actual 
treatment is probably zero, and most 
patients are discharged home within 24 
hours. The few immediate adverse 
reactions are post-procedural headaches, 
nausea and vomiting. One-tenth of patients 
with subcortical AVMs had focal or 
generalized seizures within 24 hours of 
treatment38. Long-term morbidity is more 
frequent with larger doses and treatment 
volumes, and include39: white matter 
changes, vasculopathy, cranial nerve 
deficits, induced tumors40 and normal 
perfusion pressure breakthrough41. The risk 
of hemorrhage also specifically applies to 
AVMs.Error! Bookmark not defined. 
 
Case report 
Our 59-year-old male patient presented 
a month-long history of language and 
humor disorders associated with headaches 
and right central facial paresis. 
Investigational MRI revealed an anterior 
left temporal mass, with strong 
enhancement after gadolinium, with edema 
Figure 1 – T1-weighted MRI (with gadolinium contrast) showing 
the SFT of the presented patient before the first surgery (GTR). 
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and mass effect (Figure 1). A preoperative 
embolization of the main vascular pedicles 
was performed and surgical GTR of this 
well circumscribed lesion was 
accomplished with coagulation of the 
spheno-cavernous implantation. Pathology 
examination revealed a SFT, with a mitotic 
index inferior to 4/10 high-power fields, a 
MIB1 lab index inferior to 1%, widespread 
staining for CD34 and vimentin and focal 
staining for bcl-2. Staining with EMA was 
negative. No atypical features were 
reported (Figure 2).  
During follow-up a small recurrence was 
detected on MRI after 34 months. Another 
MRI performed 4 months later showed 
regrowth of this lesion with invasion of the 
left cavernous sinus and optical nerve 
compression. Reoperation was 
recommended and, at the time of the second 
surgery, a STR was performed, leaving 
only an intracavernous sinus residue. 
Pathology once again was consistent with a 
SFT. 
The tumor residue was treated 10 
months later (48 months after the first 
surgery) with 6MV linear accelerator-based 
SRS (Trilogy®). The target volume was 
5,32cm3. One isocenter was established and 
was covered with a maximum dose of 15Gy 
to the 80% isodose line. After the treatment 
no neurological disturbance or other 
complications were observed.  
During follow-up a slow tumor regrowth 
was observed in the first 12 months after 
SRS, with posterior stabilization and 10% 
tumor volume shrinkage. The shrinkage 
was only observed 24 months post-SRS. At 
the time of this writing (113 months after 
the first surgery and 65 months post-SRS), 
the patient remains asymptomatic and the 
size of the residual lesion maintains stable 
on MRI (Figure 43). No out-of-field 
recurrences were observed.  
 
Discussion 
Despite the lack of enough data 
supporting the use of SRS in intracranial 
Figure 2 - Illustration of the fibrous pattern of the tumor, at 40x, 
both by Hematoxylin and Eosin (left) and Van Guieson (right) 
staining. 
Figure 3 - T1-weighted MRI (with gadolinium contrast), showing 
tumor presentation at time of recurrence, prior to the second 
surgery (STR). 
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SFTs, the fact is that the few cases reported 
in literature shine a light on this method as 
a valid option when GTR is not possible. 
The ability of sparing important 
surrounding structures to aggression, the 
low incidence of complications, and the 
possibility of performing the treatment in a 
single session with patient discharge home 
in 24 hours also make this modality a strong 
candidate as an alternative option to 
conventional surgery. 
In one published case report, the authors 
chose SRS to treat a patient with a slow re-
growing SFT located in the occipital region, 
after a STR. This patient was treated with 
6-MV linear accelerator–based SRS 
covering the tumor with a maximum dose 
of 24 Gy (with 21 Gy applied to the 50% 
isodose). Target size was 1,25cm3. The 
result was a decreased residual tumor size 
documented by MR imaging more than 4 
years after the procedure19. 
Reams et al. (2011) report two other 
cases using SRS. In one case, the patient 
had undergone surgery twice, both with 
STR, to a SFT also located in the occipital 
region. Because there was extensive tumor 
involvement of the torcula, straight sinus 
and bilateral transverse sinus, the patient 
underwent Gamma Knife Radiosurgery 
(GKRS) to those three separate areas of 
tumor foci, two months after the second 
surgery. Maximum dose was 27 Gy and 
margin dose was 13.5 Gy. MRI after 20 
months showed significant tumor size 
reduction of all three locations and no out-
of-field recurrences were reported. In the 
other case, the patient experienced several 
recurrences, having been surgically treated 
seven times, with two new areas of 
recurrence after the last surgical 
intervention. One of the recurrences was 
located in the right posterior cerebellar 
region and the other in the right anterior 
cerebellar region. This patient was treated 
with GKRS for both lesions. Margin doses 
were 20 Gy and 22 Gy for each recurrent 
lesion, with tumor volumes of 1,70cm3 and 
Figure 4  - T1-weighted MRI's (with gadolinium contrast) of the presented case showing tumor volume progression before and after SRS. The 
image in the left shows the SFT after STR, prior to radiosurgery. The middle image shows the patient’s SFT approximately 1 year after SRS. 
By this time, there was evidence of tumor volume growth. MRI for tumor volume calculation 2 years after SRS (right image; red line – tumor 
borders) evidenced decrease of tumor volume by around 10%. Subsequent imaging up until time of writing reported no further changes in 
tumor volume. 
Commented [E1]: Na revisão dos casos tens de dizer qual a 
localização dos tumores que foram submetidos a 
Radiocirurgia. 
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0,135cm3 respectively. Although the 13-
month follow-up MRI reported decrease in 
both tumors’ size, new out-of-field 
recurrences were reported, and she was 
again treated with GKRS 15 months after 
the first SRS intervention. One of the target 
volumes was located in the right lateral 
cerebellar region, with 0,8 cm3 and received 
22 Gy to the 50% isodose; the other was 
located in the right medial cerebellar 
region, with 1.70 cm3 and received 20 Gy 
to the 50% isodose line. Subsequent follow-
up for this patient is not reported20. 
A more recent report of two cases also 
states that SRS is associated with a 
favorable long-term outcome in patients 
with SFTs of the CNS.  In one of the cases, 
the tumor was located in the parasagittal 
right central region, while in the other the 
patient presented with a tumor located in 
the right tentorium. Both patients 
experienced multiple recurrences that were 
treated using GKRS/CKRS (Cyber-knife 
radiosurgery) or conventional surgery 
according to their preferences at each time. 
The authors report radiosurgically-treated 
tumor volumes ranging from 0.2 to 21.1 
cm3 with progression-free survival (PFS) 
times in these tumors ranging from two to 
five years. Tumor margin doses ranged 12-
15 Gy. Follow-up periods were 17 years for  
one patient and 9 years for the other, both 
being alive at time of writing of the article 
and maintaining a Karnofsky performance 
score (KPS) of 100 at all times21.  
All of the above reports advocate the 
usage of SRS in incompletely resected 
intracranial SFTs, because of its potential of 
sparing critical neurostructures adjacent to 
the tumor sites from damage and the 
seemingly positive response of SFTs when 
radiation is dealt20. The information is still 
insufficient to reach major conclusions, as 
there are only a few reports and they are 
Table 1 – Comparison of the main treatment features between the reported case and the existing literature. GKRS, Gamma-Knife Radiosurgery; 
CKRS, Cyber-knife Radiosurgery; SRS, Stereotactic Radiosurgery; PFS, progression-free survival; NA, not available. 
Case SRS modality 
Target size 
(cm3) 
Dose (Gy) PFS 
Nakahara et al. LINAC 1,25 21@50%isodose 48 months 
Reames et al. 
Case 1 GKRS NA 13,5@50%isodose 20 months 
Case 2 GKRS 
0,135 
1,7 
22@50%isodose 
20@50%isodose 
13 months 
Mindermann 
et al. 
Case 1 
GKRS 
GKRS 
GKRS 
CKRS 
CKRS 
21,1 
1,2 
0,9 
1,4 
0,2 
14@50%isodose 
15@50%isodose 
13@50%isodose 
12@70%isodose 
14@73%isodose 
60 months 
36 months 
48 months 
24 months 
NA 
Case 2 GKRS 1,2 14@50%isodose 24 months 
Reported case LINAC 5,32 15@80%isodose 65 months 
Commented [E2]: A informação da dose é expressa nesta 
nomenclatura com a utilização da @? 
Commented [E3]: Coloca meses em todos. Não anos nuns e 
meses noutros.  
Treatment of Intracranial Solitary Fibrous Tumor with Stereotactic Radiosurgery 10 
limited by factors like short follow-up 
periods19 or, in one case, simultaneous 
usage of chemotherapy (Torimifene)42. 
In our case, in comparison with the 
majority of other similar reports, we chose 
to treat the target tumor with a significantly 
lower dose of radiation (15Gy) on a larger 
tumor volume (5.32cm3). A positive tumor 
response was achieved in the long term, 
with shrinkage reported 24 months post-
procedure. This raises questions about the 
amount of radiation that is actually 
necessary to treat this subtype of lesions, 
and how it relates to the target size (Table 
1). 
There is also an interesting and unique 
feature about this case, which is the fact that 
the tumor kept slowly growing during the 
12 months post-SRS, and, only after 12 
other months, evidence on shrinkage was 
reported. None of the previously reported 
cases has ever mentioned such biological 
behavior. This further strengthens the fact 
that not only must these tumors be followed 
in the very long term but also that the 
effects of SRS may take a significant 
amount of time to take place. Additionally, 
it appears that evidence of tumor growth in 
the post-treatment period does not 
necessarily mean it has failed. The reasons 
behind this behavior are not clear. 
Radiochemistry basics state that cellular 
injury from radiation occurs either by direct 
action from DNA breakage and by indirect 
action by the generation of free radicals, 
which in turn is also responsible for DNA 
injury. This latter mechanism is actually 
responsible for the majority of radiation-
induced cell damage, owing to the existence 
of a much higher quantity of water 
molecules (from which free radicals are 
generated) than DNA material in cells. 
Because in the reported case a significantly 
lower dose of radiation was used, an 
explanation for this tumor behavior may 
come from the fact that it induced some sort 
of free-radical-mediated injury cascade that 
still allowed tumor growth in the first 
months, but eventually led to critical DNA 
injury, which dictated tumor shrinkage in 
the long-term. Another explanation may be 
related to vascular obliteration and 
endothelial damage caused by the effects of 
radiation: the tumor may have been allowed 
to grow until it ended up outside its vascular 
bed, and at that time, ischemia started to 
ensue, determining cell death and 
consequent tumor shrinkage. Because SFTs 
are typically slow-growing tumors, it would 
be logical that the observed effects took a 
significant amount of time to happen, and 
that’s precisely what happened in the case 
presented in this report.  
In addition to the radiosurgical aspects 
of our case, a short analisys of the usage of 
preoperative embolization is worthy. In 
fact, none of the reports described above in 
this discussion included this method in any 
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treatment stage of their patients. To our 
knowledge, indeed there are no formal 
indications for preoperative embolization in 
SFT surgery of any anatomical loci, 
although a few cases have been reported. 
Our view is that a successful preoperative 
embolization results in lower chances of 
perioperative complications, with a 
consequent reduction in postoperative 
recovery time. It has been adopted in our 
department as a common practice in the 
management of neurological SFTs43. 
Accordingly, the same procedure was 
performed in this patient (Figure 5), with no 
peri or postoperative complications, thus 
further supporting our positive experience 
with preoperative embolization. 
Another remarkable fact regarding this 
case is that, even with surgical GTR, and 
despite that it had no atypical histological 
features, there was recurrence of the tumor. 
A strict long-term follow-up period on 
every patient with the diagnosis of SFT is 
therefore needed. These tumors have a very 
unpredictable behavior and neither the 
extent of surgical excision nor the 
histological features can give certainty on 
whether the tumor will or not recur. 
It must also be said, however, that 
despite the apparent successful outcome of 
our case, the follow-up period is still very 
short comparing to other reported cases, 
and further surveillance for this patient is 
necessary. There have already been reports 
of local or distant recurrences post-SRS in 
other cases20,21. This owes probably to the 
unique biological features these tumors 
have in each case, which cannot still be 
fully characterized in light of current 
knowledge. Our case seems to have a less 
aggressive behavior comparing to others 
where recurrence occurred post-SRS. 
In summary, it seems that SRS does not 
obviate the need for a strict, long-term 
follow-up period on patients with 
intracranial SFTs, but it represents a viable 
option as adjuvant therapy. Further studies 
with longer follow-ups are necessary. 
 
Conclusion 
SFTs are tumors with a generally benign 
behavior, but nonetheless with an 
unpredictable outcome in the long term, 
regardless of its histological features or the 
extent of surgical excision. That being said, 
this tumor may occur or recur in anatomical 
loci that do not allow for surgical GTR. In 
Figure 5 - Embolization of the SFT prior to GTR surgery.  
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these cases, usage of SRS as adjuvant 
therapy has been scarcely reported, but with 
promising results. Our case represents 
another successful treatment using this 
method, while adding some more 
knowledge to this subject. It further 
strengthens the role of SRS on the 
management of these tumors when surgery 
alone is not enough. 
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